Meeting
2023 ASCO Genitourinary Cancers Symposium
Pembrolizumab (Pem) in metastatic castration-resistant prostate cancer (mCRPC): Experience from a comprehensive cancer center.
Authors
Arya Mariam Roy
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Arya Mariam Roy , Bailey Farmer , Vasanthan Muthusamy Kumarasamy , Karan Jatwani , Ellis Glenn Levine , Gurkamal S. Chatta , Dharmesh Gopalakrishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 113)
DOI
10.1200/JCO.2023.41.6_suppl.113
Abstract #
113
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
First Author: Evan Y. Yu
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.
First Author: Marwan Fakih
Poster
2019 Genitourinary Cancers Symposium
Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Matthew D Tucker